Maxcyte (MXCT) Gross Margin (2020 - 2025)
Maxcyte (MXCT) has disclosed Gross Margin for 6 consecutive years, with 113.69% as the latest value for Q3 2025.
- On a quarterly basis, Gross Margin rose 257.0% to 113.69% in Q3 2025 year-over-year; TTM through Sep 2025 was 143.75%, a 324.0% decrease, with the full-year FY2024 number at 141.92%, down 4553.0% from a year prior.
- Gross Margin was 113.69% for Q3 2025 at Maxcyte, up from 82.14% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 2166.22% in Q4 2024 to a low of 60.58% in Q2 2023.
- A 5-year average of 243.72% and a median of 111.12% in 2024 define the central range for Gross Margin.
- Peak YoY movement for Gross Margin: soared 293298bps in 2021, then tumbled -31628bps in 2023.
- Maxcyte's Gross Margin stood at 87.92% in 2021, then soared by 59bps to 140.24% in 2022, then soared by 111bps to 296.36% in 2023, then skyrocketed by 631bps to 2166.22% in 2024, then tumbled by -95bps to 113.69% in 2025.
- Per Business Quant, the three most recent readings for MXCT's Gross Margin are 113.69% (Q3 2025), 82.14% (Q2 2025), and 154.85% (Q1 2025).